Prevacid Follow-On NDA To Be Submitted In 2008
This article was originally published in The Pink Sheet Daily
Executive Summary
TAP is preparing to start Phase III clinical trials for TAK-390MR, an enantiomer of Prevacid (lansoprazole).
You may also be interested in...
TAP Files NDA For Prevacid Follow-On To Treat GERD-Related Illnesses
Secret of novel delivery system, trial data for TAK-390MR will be revealed at Digestive Disease Week conference in May, TAP VP-Gastrointestinal Marketing Rudolphi tells “The Pink Sheet” DAILY.”
TAP Files NDA For Prevacid Follow-On To Treat GERD-Related Illnesses
Secret of novel delivery system, trial data for TAK-390MR will be revealed at Digestive Disease Week conference in May, TAP VP-Gastrointestinal Marketing Rudolphi tells “The Pink Sheet” DAILY.”
TAP Licenses Investigational PPI As Part Of Gastroenterological Focus
New investigational proton pump inhibitor, licensed from Seoul, Korea-based Ilyang, will enter Phase II trials in 2006, TAP reports.